ACOR stock forecast
Our latest prediction for Acorda Therapeutics, Inc.'s stock price was made on the Dec. 28, 2018 when the stock price was at 14.98$.
In the short term (2weeks), ACOR's stock price should underperform the market by -0.07%. During that period the price should oscillate between -9.45% and +10.85%.
In the medium term (3months), ACOR's stock price should outperform the market by 1.38%. During that period the price should oscillate between -20.26% and +28.12%.Get email alerts
Create a solid portfolio with ACOR
About Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its products include AMPYRA (dalfampridine), INBRIJA (levodopa inhalation powder), BTT1023 (timolumab), SYN120, rHIgM22, and GGF2 (Cimaglermin alfa). The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.
At the moment the company generates 591M USD in revenues.
On its last earning announcement, the company reported a loss of -3.21$ per share.
The book value per share is 12.78$
Three months stock forecastDec. 28, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|